Coherus Oncology (CHRS) Competitors

$1.40 +0.01 (+0.72%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$1.43 +0.03 (+2.07%)

As of 07/17/2026 07:55 PM Eastern

CHRS vs. TBPH, DSGN, REPL, PHAT, and AMPH

Should you buy Coherus Oncology stock or one of its competitors? MarketBeat compares Coherus Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Coherus Oncology include Theravance Biopharma (TBPH), Design Therapeutics (DSGN), Replimune Group (REPL), Phathom Pharmaceuticals (PHAT), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry.

How does Coherus Oncology compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Theravance Biopharma has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

In the previous week, Theravance Biopharma had 4 more articles in the media than Coherus Oncology. MarketBeat recorded 4 mentions for Theravance Biopharma and 0 mentions for Coherus Oncology. Theravance Biopharma's average media sentiment score of 0.62 beat Coherus Oncology's score of 0.00 indicating that Theravance Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Theravance Biopharma	Positive
Coherus Oncology	Neutral

Theravance Biopharma presently has a consensus price target of $19.40, indicating a potential upside of 14.59%. Coherus Oncology has a consensus price target of $8.67, indicating a potential upside of 519.05%. Given Coherus Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Coherus Oncology is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 7.7% of Theravance Biopharma shares are owned by insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Coherus Oncology has a net margin of 397.30% compared to Theravance Biopharma's net margin of 104.34%. Theravance Biopharma's return on equity of 18.84% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	104.34%	18.84%	10.94%
Coherus Oncology	397.30%	-198.90%	-46.65%

Coherus Oncology has lower revenue, but higher earnings than Theravance Biopharma. Coherus Oncology is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	8.12	$105.89M	$2.20	7.70
Coherus Oncology	$42.17M	5.12	$168.02M	$1.67	0.84

Summary

Theravance Biopharma beats Coherus Oncology on 9 of the 16 factors compared between the two stocks.

How does Coherus Oncology compare to Design Therapeutics?

Coherus Oncology (NASDAQ:CHRS) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Coherus Oncology presently has a consensus target price of $8.67, suggesting a potential upside of 519.05%. Design Therapeutics has a consensus target price of $16.50, suggesting a potential upside of 31.26%. Given Coherus Oncology's higher possible upside, research analysts clearly believe Coherus Oncology is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

72.8% of Coherus Oncology shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 8.1% of Coherus Oncology shares are held by insiders. Comparatively, 17.1% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Coherus Oncology has a net margin of 397.30% compared to Design Therapeutics' net margin of 0.00%. Design Therapeutics' return on equity of -33.07% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
Design Therapeutics	N/A	-33.07%	-31.29%

Coherus Oncology has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

Coherus Oncology has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	5.12	$168.02M	$1.67	0.84
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

In the previous week, Design Therapeutics had 3 more articles in the media than Coherus Oncology. MarketBeat recorded 3 mentions for Design Therapeutics and 0 mentions for Coherus Oncology. Design Therapeutics' average media sentiment score of 0.54 beat Coherus Oncology's score of 0.00 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Coherus Oncology	Neutral
Design Therapeutics	Positive

Summary

Design Therapeutics beats Coherus Oncology on 9 of the 16 factors compared between the two stocks.

How does Coherus Oncology compare to Replimune Group?

Replimune Group (NASDAQ:REPL) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

Replimune Group has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

In the previous week, Replimune Group had 7 more articles in the media than Coherus Oncology. MarketBeat recorded 7 mentions for Replimune Group and 0 mentions for Coherus Oncology. Replimune Group's average media sentiment score of 0.92 beat Coherus Oncology's score of 0.00 indicating that Replimune Group is being referred to more favorably in the media.

Company	Overall Sentiment
Replimune Group	Positive
Coherus Oncology	Neutral

Replimune Group currently has a consensus price target of $8.13, indicating a potential downside of 20.58%. Coherus Oncology has a consensus price target of $8.67, indicating a potential upside of 519.05%. Given Coherus Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Coherus Oncology is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Coherus Oncology has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.38	N/A
Coherus Oncology	$42.17M	5.12	$168.02M	$1.67	0.84

Coherus Oncology has a net margin of 397.30% compared to Replimune Group's net margin of 0.00%. Replimune Group's return on equity of -128.57% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-128.57%	-82.35%
Coherus Oncology	397.30%	-198.90%	-46.65%

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 5.2% of Replimune Group shares are owned by insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Coherus Oncology beats Replimune Group on 11 of the 15 factors compared between the two stocks.

How does Coherus Oncology compare to Phathom Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Phathom Pharmaceuticals has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

Coherus Oncology has a net margin of 397.30% compared to Phathom Pharmaceuticals' net margin of -76.77%. Phathom Pharmaceuticals' return on equity of 0.00% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Coherus Oncology	397.30%	-198.90%	-46.65%

Coherus Oncology has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	4.98	-$221.25M	-$2.12	N/A
Coherus Oncology	$42.17M	5.12	$168.02M	$1.67	0.84

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Phathom Pharmaceuticals had 2 more articles in the media than Coherus Oncology. MarketBeat recorded 2 mentions for Phathom Pharmaceuticals and 0 mentions for Coherus Oncology. Phathom Pharmaceuticals' average media sentiment score of 0.30 beat Coherus Oncology's score of 0.00 indicating that Phathom Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Phathom Pharmaceuticals	Neutral
Coherus Oncology	Neutral

Phathom Pharmaceuticals currently has a consensus target price of $24.50, suggesting a potential upside of 123.95%. Coherus Oncology has a consensus target price of $8.67, suggesting a potential upside of 519.05%. Given Coherus Oncology's higher probable upside, analysts plainly believe Coherus Oncology is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Phathom Pharmaceuticals beats Coherus Oncology on 10 of the 17 factors compared between the two stocks.

How does Coherus Oncology compare to Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

In the previous week, Amphastar Pharmaceuticals had 2 more articles in the media than Coherus Oncology. MarketBeat recorded 2 mentions for Amphastar Pharmaceuticals and 0 mentions for Coherus Oncology. Amphastar Pharmaceuticals' average media sentiment score of 0.85 beat Coherus Oncology's score of 0.00 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Amphastar Pharmaceuticals	Positive
Coherus Oncology	Neutral

Amphastar Pharmaceuticals presently has a consensus price target of $22.00, suggesting a potential upside of 11.39%. Coherus Oncology has a consensus price target of $8.67, suggesting a potential upside of 519.05%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Coherus Oncology is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	3 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.63
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Coherus Oncology has lower revenue, but higher earnings than Amphastar Pharmaceuticals. Coherus Oncology is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.21	$98.09M	$1.66	11.90
Coherus Oncology	$42.17M	5.12	$168.02M	$1.67	0.84

Amphastar Pharmaceuticals has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Coherus Oncology has a net margin of 397.30% compared to Amphastar Pharmaceuticals' net margin of 11.00%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Coherus Oncology	397.30%	-198.90%	-46.65%

Summary

Coherus Oncology beats Amphastar Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Coherus Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CHRS vs. The Competition

Export

Metric	Coherus Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$215.95M	$3.69B	$7.01B	$12.29B
Dividend Yield	N/A	2.17%	2.67%	9.35%
P/E Ratio	0.84	21.03	27.25	23.90
Price / Sales	5.12	304.50	527.76	91.71
Price / Cash	N/A	60.31	29.05	48.09
Price / Book	2.80	8.28	10.70	6.18
Net Income	$168.02M	$23.81M	$3.59B	$332.02M
7 Day Performance	-9.09%	-3.47%	-2.20%	-2.05%
1 Month Performance	-5.41%	2.69%	1.63%	-2.18%
1 Year Performance	58.95%	45.93%	25.64%	17.67%

Coherus Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CHRS Coherus Oncology	2.1852 of 5 stars	$1.40 +0.7%	$8.67 +519.0%	+58.9%	$215.95M	$42.17M	0.84	330
TBPH Theravance Biopharma	3.0999 of 5 stars	$16.94 +0.2%	$19.40 +14.6%	+50.5%	$872.74M	$107.46M	7.70	110	News Coverage
DSGN Design Therapeutics	2.3435 of 5 stars	$13.89 +0.3%	$16.50 +18.8%	+215.8%	$872.50M	N/A	N/A	40	News Coverage Positive News
REPL Replimune Group	1.2105 of 5 stars	$10.29 +3.5%	$8.13 -21.0%	-15.4%	$857.03M	N/A	N/A	210	News Coverage
PHAT Phathom Pharmaceuticals	1.945 of 5 stars	$10.77 -1.3%	$24.50 +127.4%	+37.6%	$857.02M	$175.11M	N/A	110	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CHRS) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coherus Oncology (CHRS) Competitors

CHRS vs. TBPH, DSGN, REPL, PHAT, and AMPH

How does Coherus Oncology compare to Theravance Biopharma?

Summary

How does Coherus Oncology compare to Design Therapeutics?

Summary

How does Coherus Oncology compare to Replimune Group?

Summary

How does Coherus Oncology compare to Phathom Pharmaceuticals?

Summary

How does Coherus Oncology compare to Amphastar Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS vs. The Competition

Coherus Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coherus Oncology (CHRS) Competitors

CHRS vs. TBPH, DSGN, REPL, PHAT, and AMPH

How does Coherus Oncology compare to Theravance Biopharma?

Which has more risk & volatility, TBPH or CHRS?

Does the media prefer TBPH or CHRS?

Do analysts prefer TBPH or CHRS?

Do institutionals & insiders have more ownership in TBPH or CHRS?

Is TBPH or CHRS more profitable?

Which has higher earnings & valuation, TBPH or CHRS?

Summary

How does Coherus Oncology compare to Design Therapeutics?

Do analysts prefer CHRS or DSGN?

Do insiders & institutionals hold more shares of CHRS or DSGN?

Is CHRS or DSGN more profitable?

Which has more volatility & risk, CHRS or DSGN?

Which has stronger earnings and valuation, CHRS or DSGN?

Does the media favor CHRS or DSGN?

Summary

How does Coherus Oncology compare to Replimune Group?

Which has more risk & volatility, REPL or CHRS?

Does the media prefer REPL or CHRS?

Do analysts recommend REPL or CHRS?

Which has better valuation and earnings, REPL or CHRS?

Is REPL or CHRS more profitable?

Do insiders and institutionals have more ownership in REPL or CHRS?

Summary

How does Coherus Oncology compare to Phathom Pharmaceuticals?

Which has more risk and volatility, PHAT or CHRS?

Is PHAT or CHRS more profitable?

Which has preferable valuation & earnings, PHAT or CHRS?

Do insiders and institutionals hold more shares of PHAT or CHRS?

Does the media prefer PHAT or CHRS?

Do analysts rate PHAT or CHRS?

Summary

How does Coherus Oncology compare to Amphastar Pharmaceuticals?

Does the media prefer AMPH or CHRS?

Do analysts rate AMPH or CHRS?

Which has stronger earnings and valuation, AMPH or CHRS?

Which has more volatility and risk, AMPH or CHRS?

Do institutionals & insiders hold more shares of AMPH or CHRS?

Is AMPH or CHRS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS vs. The Competition

Coherus Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools